Opthea Limited
ASX:OPT.AX
Overview | Financials
Company Name | Opthea Limited |
Symbol | OPT.AX |
Currency | AUD |
Price | 0.835 |
Market Cap | 1,027,960,150 |
Dividend Yield | 0% |
52-week-range | 0.315 - 0.955 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D. |
Website | https://opthea.com |
An error occurred while fetching data.
About Opthea Limited
Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD